Author: Ravi Shankar

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland, September 28, 2026 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update.

“The successful raising of USD 2.8 million during the last quarter enables us to continue advancing our in-house GABAB cough program towards clinical development. Coupled with recent regaining of all rights to the GABAB PAM program for substance use disorders from Indivior, due to R&D rationalization following its merger with Supernus Pharmaceuticals, providing a valuable asset for Addex and solidifying our leading portfolio of drug candidates targeting GABAB receptor biology. Our spin-out company, Neurosterix made as well great progress and is on track to complete its Phase 1 clinical study with NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, during the fourth quarter of 2026,” said Tim Dyer, CEO of Addex.

Operating Highlights:

• Raised USD 2.8 million (CHF 2.2 million) through At the Market (ATM) offering agreement with H.C Wainwright & Co
• Regained rights to GABAB positive allosteric modulator portfolio from Indivior
• Spin-out company, Neurosterix continued to progress through Phase 1 clinical development with the M4 PAM candidate, NTX-253
• Continued advancing GABAB PAM chronic cough candidate through preclinical development

Key H1 2026 Financial Data

CHF’ thousands	Q2 26	Q2 25	Change	H1 26	H1 25	Change
Income	10	36	(26)	18	107	(89)
R&D expenses	(38)	(234)	196	(74)	(391)	317
G&A expenses	(617)	(535)	(82)	(1,069)	(1,056)	(13)
Total operating loss	(645)	(733)	88	(1,125)	(1,339)	214
Finance result, net	2	6	(4)	–	(13)	13
Share of net loss of associates	(1,102)	(1,232)	130	(2,331)	(2,079)	(252)
Net loss from continuing operations	(1,745)	(1,959)	213	(3,456)	(3,432)	(24)
Net profit from discontinued operations	–	118	(118)	–	118	(118)
Net loss for the period	(1,745)	(1,841)	95	(3,456)	(3,314)	(142)
Basic and diluted net loss per share	(0.01)	(0.02)	0.01	(0.03)	(0.03)	–
Net decrease in cash during the period	(168)	(524)	356	(872)	(1,041)	169
Cash and cash equivalents as of June 30	767	2,301	(1,534)	767	2,301	(1,534)
Shareholders’ equity	1,909	7,213	(5,304)	1,909	7,213	(5,304)

Financial Summary:

Income, primarily related to the fair value of the services received from Neurosterix’s Group at zero cost, decreased by CHF 0.1 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025.

R&D expenses decreased by CHF 0.3 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025, primarily due to decreased GABAB PAM outsourced R&D expenses and reduced services received at zero cost from Neurosterix’s Group.

G&A expenses, primarily driven by staff costs and professional fees, remained stable around CHF 1.1 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025.

The net result decreased by CHF 0.1 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025, primarily due to reduced R&D expenses partially offset by an increased share of the net loss of Neurosterix’s Group.

Basic and diluted loss per share remained stable at CHF 0.03 per share for the six-month periods ended June 30, 2026 and 2025.

Cash and cash equivalents decreased to CHF 0.8 million at June 30, 2026, compared to CHF 2.3 million at June 30, 2025. The decrease of CHF 1.5 million between June 30, 2026, and June 30, 2025, is primarily due to operating activities partially offset by the sale of treasury shares and ADSs.

Post balance sheet event: From July 1, 2026 to August 25, 2026, the Group sold 52,970,533 shares at an average price of CHF 0.043 (USD 0.053) for total gross proceeds of CHF 2.3 million (USD 2.8 million).

2026 Half-Year Consolidated Financial Statements:
The 2026 Half-Year financial report can be found on the Company’s website in the investor/download section here.

Conference Call Details:
A conference call will be held today, on September 28, 2026, at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to review the financial results. Tim Dyer, Chief Executive Officer and Mikhail Kalinichev, Head of Translational Science, will deliver a brief presentation followed by a Q&A session.

Joining the Conference Call:

1. Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
2. In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.

Webcast registration link: Registration webcast

Conference call registration link: Registration conference media

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is a Phase 2 ready asset under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex is developing a GABAB PAM drug candidate for substance use disorders that has successfully completed IND enabling studies and a second GABAB PAM program for chronic cough, which is ready to start IND enabling studies. Addex holds a 20% equity interest in a private spin-out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders, and a mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.                                       

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com.
  
Contacts: 

Tim Dyer  Chief Executive Officer  Telephone: +41 22 884 15 55  PR@addextherapeutics.com

Mike Sinclair  Partner, Halsin Partners  +44 (0)7968 022075  msinclair@halsin.com

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland, September 28, 2026 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update.

“The successful raising of USD 2.8 million during the last quarter enables us to continue advancing our in-house GABAB cough program towards clinical development. Coupled with recent regaining of all rights to the GABAB PAM program for substance use disorders from Indivior, due to R&D rationalization following its merger with Supernus Pharmaceuticals, providing a valuable asset for Addex and solidifying our leading portfolio of drug candidates targeting GABAB receptor biology. Our spin-out company, Neurosterix made as well great progress and is on track to complete its Phase 1 clinical study with NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, during the fourth quarter of 2026,” said Tim Dyer, CEO of Addex.

Operating Highlights:

• Raised USD 2.8 million (CHF 2.2 million) through At the Market (ATM) offering agreement with H.C Wainwright & Co
• Regained rights to GABAB positive allosteric modulator portfolio from Indivior
• Spin-out company, Neurosterix continued to progress through Phase 1 clinical development with the M4 PAM candidate, NTX-253
• Continued advancing GABAB PAM chronic cough candidate through preclinical development

Key H1 2026 Financial Data

CHF’ thousands	Q2 26	Q2 25	Change	H1 26	H1 25	Change
Income	10	36	(26)	18	107	(89)
R&D expenses	(38)	(234)	196	(74)	(391)	317
G&A expenses	(617)	(535)	(82)	(1,069)	(1,056)	(13)
Total operating loss	(645)	(733)	88	(1,125)	(1,339)	214
Finance result, net	2	6	(4)	–	(13)	13
Share of net loss of associates	(1,102)	(1,232)	130	(2,331)	(2,079)	(252)
Net loss from continuing operations	(1,745)	(1,959)	213	(3,456)	(3,432)	(24)
Net profit from discontinued operations	–	118	(118)	–	118	(118)
Net loss for the period	(1,745)	(1,841)	95	(3,456)	(3,314)	(142)
Basic and diluted net loss per share	(0.01)	(0.02)	0.01	(0.03)	(0.03)	–
Net decrease in cash during the period	(168)	(524)	356	(872)	(1,041)	169
Cash and cash equivalents as of June 30	767	2,301	(1,534)	767	2,301	(1,534)
Shareholders’ equity	1,909	7,213	(5,304)	1,909	7,213	(5,304)

Financial Summary:

Income, primarily related to the fair value of the services received from Neurosterix’s Group at zero cost, decreased by CHF 0.1 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025.

R&D expenses decreased by CHF 0.3 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025, primarily due to decreased GABAB PAM outsourced R&D expenses and reduced services received at zero cost from Neurosterix’s Group.

G&A expenses, primarily driven by staff costs and professional fees, remained stable around CHF 1.1 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025.

The net result decreased by CHF 0.1 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025, primarily due to reduced R&D expenses partially offset by an increased share of the net loss of Neurosterix’s Group.

Basic and diluted loss per share remained stable at CHF 0.03 per share for the six-month periods ended June 30, 2026 and 2025.

Cash and cash equivalents decreased to CHF 0.8 million at June 30, 2026, compared to CHF 2.3 million at June 30, 2025. The decrease of CHF 1.5 million between June 30, 2026, and June 30, 2025, is primarily due to operating activities partially offset by the sale of treasury shares and ADSs.

Post balance sheet event: From July 1, 2026 to August 25, 2026, the Group sold 52,970,533 shares at an average price of CHF 0.043 (USD 0.053) for total gross proceeds of CHF 2.3 million (USD 2.8 million).

2026 Half-Year Consolidated Financial Statements:
The 2026 Half-Year financial report can be found on the Company’s website in the investor/download section here.

Conference Call Details:
A conference call will be held today, on September 28, 2026, at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to review the financial results. Tim Dyer, Chief Executive Officer and Mikhail Kalinichev, Head of Translational Science, will deliver a brief presentation followed by a Q&A session.

Joining the Conference Call:

1. Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
2. In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.

Webcast registration link: Registration webcast

Conference call registration link: Registration conference media

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is a Phase 2 ready asset under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex is developing a GABAB PAM drug candidate for substance use disorders that has successfully completed IND enabling studies and a second GABAB PAM program for chronic cough, which is ready to start IND enabling studies. Addex holds a 20% equity interest in a private spin-out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders, and a mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.                                       

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com.
  
Contacts: 

Tim Dyer  Chief Executive Officer  Telephone: +41 22 884 15 55  PR@addextherapeutics.com

Mike Sinclair  Partner, Halsin Partners  +44 (0)7968 022075  msinclair@halsin.com

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Aktsiaselts Infortar acquired its own shares on the Nasdaq Tallinn Stock Exchange during the period of 21 September – 25 September 2026 as follows:

Date	Aggregated volume (pcs)	Weighted average price per day (EUR)
21.09.2026	227	59,7436
22.09.2026	222	59,8432
23.09.2026	221	59,9240
24.09.2026	225	59,9031
25.09.2026	224	60,9429

Aktsiaselts Infortar is acquiring its own shares based on the stock exchange announcement published on 20 April 2026. The share buyback programme is managed by SEB Pank AS, which will buy back shares on behalf of Aktsiaselts Infortar.

Summary data (daily volume and weighted average prices) will be disclosed no later than on the seventh trading day following the transaction and be made available to the Estonian Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Aktsiaselts Infortar´s investor website.

Further detailed information on the transactions is attached.

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.83% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 141,000 m². In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 107 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Infortar employs 6890 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

Attachment

• INF buyback_ENG

Aktsiaselts Infortar acquired its own shares on the Nasdaq Tallinn Stock Exchange during the period of 21 September – 25 September 2026 as follows:

Date	Aggregated volume (pcs)	Weighted average price per day (EUR)
21.09.2026	227	59,7436
22.09.2026	222	59,8432
23.09.2026	221	59,9240
24.09.2026	225	59,9031
25.09.2026	224	60,9429

Aktsiaselts Infortar is acquiring its own shares based on the stock exchange announcement published on 20 April 2026. The share buyback programme is managed by SEB Pank AS, which will buy back shares on behalf of Aktsiaselts Infortar.

Summary data (daily volume and weighted average prices) will be disclosed no later than on the seventh trading day following the transaction and be made available to the Estonian Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Aktsiaselts Infortar´s investor website.

Further detailed information on the transactions is attached.

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.83% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 141,000 m². In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 107 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Infortar employs 6890 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

Attachment

• INF buyback_ENG

New expert-led services platform will help healthcare providers develop, implement, and optimize proton therapy and advanced radiation oncology programs across the full care delivery lifecycle

PHILADELPHIA, Pa., and LOUVAIN-LA-NEUVE, Belgium, 28 September 2026, 7 a.m. CEST — Penn Medicine and IBA today announced the formation of Noventra Oncology Alliance, a new joint venture designed to help healthcare providers successfully develop, implement, and optimize proton therapy and advanced radiation oncology programs. The new company will provide an integrated service offering spanning strategic and financial planning, clinical readiness, program implementation, and long-term operational performance.

The new company brings together the clinical, operational, research, and education expertise of Penn Medicine with IBA’s global leadership in proton therapy technology, project development, and implementation capabilities. The joint venture will provide integrated advisory and lifecycle support services that help healthcare organizations navigate the complexities of developing and sustaining successful proton therapy programs.

As proton therapy becomes an increasingly important component of comprehensive cancer care, health systems around the world are seeking to expand access while ensuring clinical excellence and financial sustainability. However, developing and operating a successful proton therapy program requires more than equipment acquisition. Organizations must address challenges related to strategic planning, capital investment, reimbursement, workforce development, clinical readiness, operational performance, research infrastructure, and long-term program growth.

“By combining Penn Medicine’s decades of experience building and operating one of the world’s leading proton therapy programs with IBA’s expertise in proton therapy technology and implementation, we are creating a unique platform to help healthcare organizations deliver exceptional care to patients while building sustainable, high-performing oncology programs,” said James Metz, MD, chair of Radiation Oncology at the University of Pennsylvania Perelman School of Medicine.

“A center that is unable to treat patients at scale or operate sustainably ultimately falls short of its purpose. By bringing together IBA’s global expertise in proton therapy technology and project implementation with Penn Medicine’s clinical and operational leadership, Noventra Oncology Alliance helps organizations reduce the clinical, operational, and financial risks associated with developing advanced radiation oncology programs. It will also be key to reinforcing the value of this technology in cancer treatment and accelerating its broader adoption” added Henri de Romrée, Deputy CEO of IBA.

Unlike traditional advisory models, the joint venture combines the perspectives of a world-leading clinical operator and the global leader in proton therapy technology, creating a single partner that can support organizations from initial strategy through long-term operational excellence.

Visit Noventra’s website or IBA’s booth (#843) and Penn Medicine’s booth (#1722) during the ASTRO Annual Meeting 2026 in Boston to learn more about Noventra’s services.

***ENDS***

About Penn Medicine

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

CONTACTS
Thomas Pevenage
Investor relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

Attachment

• 260928-Noventra-JV-PennM-IBA-EN

New expert-led services platform will help healthcare providers develop, implement, and optimize proton therapy and advanced radiation oncology programs across the full care delivery lifecycle

PHILADELPHIA, Pa., and LOUVAIN-LA-NEUVE, Belgium, 28 September 2026, 7 a.m. CEST — Penn Medicine and IBA today announced the formation of Noventra Oncology Alliance, a new joint venture designed to help healthcare providers successfully develop, implement, and optimize proton therapy and advanced radiation oncology programs. The new company will provide an integrated service offering spanning strategic and financial planning, clinical readiness, program implementation, and long-term operational performance.

The new company brings together the clinical, operational, research, and education expertise of Penn Medicine with IBA’s global leadership in proton therapy technology, project development, and implementation capabilities. The joint venture will provide integrated advisory and lifecycle support services that help healthcare organizations navigate the complexities of developing and sustaining successful proton therapy programs.

As proton therapy becomes an increasingly important component of comprehensive cancer care, health systems around the world are seeking to expand access while ensuring clinical excellence and financial sustainability. However, developing and operating a successful proton therapy program requires more than equipment acquisition. Organizations must address challenges related to strategic planning, capital investment, reimbursement, workforce development, clinical readiness, operational performance, research infrastructure, and long-term program growth.

“By combining Penn Medicine’s decades of experience building and operating one of the world’s leading proton therapy programs with IBA’s expertise in proton therapy technology and implementation, we are creating a unique platform to help healthcare organizations deliver exceptional care to patients while building sustainable, high-performing oncology programs,” said James Metz, MD, chair of Radiation Oncology at the University of Pennsylvania Perelman School of Medicine.

“A center that is unable to treat patients at scale or operate sustainably ultimately falls short of its purpose. By bringing together IBA’s global expertise in proton therapy technology and project implementation with Penn Medicine’s clinical and operational leadership, Noventra Oncology Alliance helps organizations reduce the clinical, operational, and financial risks associated with developing advanced radiation oncology programs. It will also be key to reinforcing the value of this technology in cancer treatment and accelerating its broader adoption” added Henri de Romrée, Deputy CEO of IBA.

Unlike traditional advisory models, the joint venture combines the perspectives of a world-leading clinical operator and the global leader in proton therapy technology, creating a single partner that can support organizations from initial strategy through long-term operational excellence.

Visit Noventra’s website or IBA’s booth (#843) and Penn Medicine’s booth (#1722) during the ASTRO Annual Meeting 2026 in Boston to learn more about Noventra’s services.

***ENDS***

About Penn Medicine

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

CONTACTS
Thomas Pevenage
Investor relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

Attachment

• 260928-Noventra-JV-PennM-IBA-EN

H1 2026 RESULTS
DIGITAL MARKETING GROWTH AND IMPROVED PROFITABILITY

• Revenue: €121.9m (+3.9%)
• Net revenue: €90.3m (+2.2%)
• Restated EBITDA: €11.9m (+11.7%)
• Net income (Group share): €6.1m (+58.9%), representing 6.7% of net revenue
• Continued European expansion in Communication and Data Marketing

Paris, September 28, 2026 (7:00 a.m.) – DEKUPLE Group, an international Communication and Data Marketing company, delivered disciplined growth and significantly improved profitability in the first half of 2026.

Bertrand Laurioz, Chairman and Chief Executive Officer of Dekuple Group, said:
“In a persistently demanding environment, DEKUPLE Group continues to deliver disciplined growth while significantly improving profitability. Restated EBITDA increased by 11.7% to €11.9m, bringing the EBITDA margin to 13.2% of net revenue, up 111 basis points compared with a challenging first half of 2025. EBIT increased by 25.3% while net income (Group share) rose by 58.9%.

These results reflect the impact of the investments made in recent years in our expertise, technologies and international development, and reinforce our profitable growth trajectory.

This improvement is notably based on the ramp-up of Digital Marketing, the Group’s main growth driver, and the increasing contribution of our international operations. This momentum also reflects the benefits of the integrated model we are building by bringing together our Consulting, Agencies and Solutions expertise and developing synergies between data, marketing technologies, creativity and artificial intelligence. We are therefore gradually becoming able to further industrialize our offerings, increase their added value and better support our clients across all their marketing needs.

At the same time, we are continuing to manage our historical businesses selectively. In Magazines, we are continuing to digitalize our operations and focusing investments on the highest value-creating levers in a structurally declining press market. With regard to Insurance, the strategic review under way should enable us to identify the most appropriate options to support its long-term development as part of our Ambition 2030 plan.

The marketing industry is rapidly evolving towards more integrated and increasingly performance-oriented models. Advertisers expect their partners to combine strategic expertise, strong command of data, technology and execution capabilities, while providing increasingly precise measurements of investment performance. We have chosen to anticipate this shift by building a multi-expertise model capable of interconnecting these different skills and mobilizing them toward a single objective: creating more value for our clients.

Building on this momentum and a solid financial structure, we approach the second half of the year with confidence. Our priority is clear: continue rolling out Ambition 2030, accelerate our expansion in Europe and strengthen synergies between our businesses in order to become a major growth partner for brands.”

First-half highlights

In the first half of 2026, DEKUPLE Group continued its growth trajectory, supported by the strong performance of its Digital Marketing activities, accelerated international development and continued organic growth.

Digital Marketing activities represented 72.7% of consolidated revenue, compared with 69.6% one year earlier. Their net revenue increased by 8.4%, including 6.0% on a like-for-like basis, driven by strong momentum in Consulting & Technology and Agencies & Solutions.

This momentum was accompanied by strong growth in international activities, whose net revenue increased by 37.1%. International operations now represent 15.3% of Group net revenue, compared with 11.4% one year earlier. The Group also continued to pursue its international external growth strategy, notably through the creation of Das Kapital DEKUPLE Group in the Middle East and the acquisition of Subko & Co in Poland, with their results consolidated from July 1, 2026.

Magazines business recorded a 7.0% decline in net revenue in a structurally declining press market. The Group continues to manage its commercial investments selectively in order to preserve the recurring nature and quality of its revenues.

In Insurance, the strategic review under way is continuing in order to identify the most appropriate options to support the business’s long-term development as part of the Ambition 2030 plan.

First-half results

Consolidated revenue¹ amounted to €121.9m, up 3.9%, while net revenue² reached €90.3m, up 2.2%.

Restated EBITDA³ amounted to €11.9m, up 11.7% compared with a difficult first half of 2025. It represented 13.2% of first-half net revenue, compared with 12.0% in the first half of 2025, an improvement of 111 basis points.

Income from ordinary operations amounted to €8.1m, representing 8.9% of first-half net revenue, compared with €6.5m and 7.4% in the first half of 2025. EBIT also amounted to €8.1m, compared with €6.4m in the first half of 2025. These results notably reflect:

• solid growth in earnings from Agencies & Solutions, driven by the increasing contribution of international operations and the development of technology offerings;
• Consulting profitability remained affected by continued investment in international development, notably in the United States and Spain, and by increased investment in AI and technology, despite a slight improvement in project profitability;
• the lower contribution of the Magazines business to profitability, given the decline in the portfolio.

After a net financial expense of €0.5m and an income tax expense of €1.7m, consolidated net income amounted to €5.8m, representing a net margin of 6.4% of net revenue, compared with 4.2% in the first half of 2025.

After non-controlling interests, net income (Group share) amounted to €6.1m, up 58.9% compared with the first half of 2025.

(€m)	H1 2026	H1 2025	Change
Revenue	121.9	117.4	+3.9%
Net revenue	90.3	88.3	+2.2%
Restated EBITDA	11.9	10.6	+11.7%
As % of net revenue	13.2%	12.0%	+111 bp
Income from ordinary operations	8.1	6.5	+23.5%
As % of net revenue	8.9%	7.4%	+154 bp
EBIT	8.1	6.4	+25.3%
As % of net revenue	8.9%	7.3%	+164 bp
Net financial expense / income	(0.5)	(0.0)
Tax expense	(1.7)	(2.8)
Share of net income from associates	0.0	0.0
Consolidated net income	5.8	3.7	+57.2%
As % of net revenue	6.4%	4.2%	+223 bp
Net income (Group share)	6.1	3.8	+58.9%
As % of net revenue	6.7%	4.3%	+239 bp

Financial position at June 30, 2026

The Group’s shareholders’ equity at June 30, 2026 amounted to €55.6m, up €0.9m compared with December 31, 2025 (€54.7m).

Group cash amounted to €45.3m, compared with €55.0m at December 31, 2025 and €45.8m at June 30, 2025.

Financial debt amounted to €58.0m, down €3.2m compared with year-end 2025 (€61.2m). It includes commitments to buy out minority interests (€20.1m), down from year-end 2025 following additional share acquisitions in certain Group subsidiaries. It also includes €36.4m in bank borrowings, of which €26.2m was drawn under the syndicated credit facility established in November 2025.

Net cash/(debt)⁴ therefore amounted to €(12.7)m, compared with €(6.3)m at year-end 2025 and €(7.8)m at June 30, 2025, reflecting in particular the level of investment and external growth transactions completed over the past twelve months.

Outlook

Building on the momentum recorded in the first half, DEKUPLE Group is continuing to roll out its Ambition 2030 strategic plan, with the aim of accelerating its expansion in Europe while strengthening synergies between its areas of expertise.

The Group is actively developing its digital and international activities, continuing to industrialize marketing performance around the convergence of data, technology, artificial intelligence and creativity, and developing high-value recurring revenues.

Drawing on its financial resources and multi-expertise model, DEKUPLE Group will also continue an active policy of investment in technology and targeted external growth in order to strengthen its European leadership in Communication and Data Marketing.

Additional information

The corporate and consolidated financial statements for the first half of 2026 were approved by the Board of Directors on September 25, 2026. The financial statements have been subject to the usual limited review by the statutory auditors for half-year accounts. The half-year financial report will be published on September 30, 2026, after market close, and will be available on the company website at: https://www.dekuple.com/investisseurs/actualites-documents-presentations/

Next event

Revenue and net revenue for the third quarter of 2026, on November 23, 2026, before market opening.

About Dekuple Group

Dekuple Group is an international player in communication, marketing and data, driven by a unique multi-entrepreneurship model. Its integrated growth platform is built around three interconnected and complementary pillars:

• Advise, with Converteo and its 450 expert consultants
• Create, with its multi-expertise agencies in France and internationally
• Boost, with its Boost Factory bringing together its Data and MarTech solutions

With nearly 70 areas of expertise covering the entire communication and data marketing value chain, the Group supports brands in their differentiation and growth challenges. Its integrated approach, through a full-funnel ecosystem, makes it possible to optimize marketing investments and increase their impact.

Founded in 1972, Dekuple Group is present in Europe, North America, China and the Middle East. Its 1,200 employees support more than 750 major accounts and international mid-sized companies every day. Dekuple is listed on the regulated market of Euronext Paris.

www.dekuple.com

Financial Communications Contacts Actus Finance & Communication Cyril Combe – Analysts – Investors +33 1 53 65 37 94 Fatou-Kiné N’Diaye – Press – Media +33 1 53 67 36 34 dekuple@actus.fr

Dekuple Group Contact Investor Relations & Financial Information + 33 (0)1 41 58 72 03 relations.investisseurs@dekuple.com

---

1 Revenue (determined in line with the French professional status for subscription sales) only include the amount of remuneration paid by magazine publishers; for subscription sales, net sales therefore correspond to a net revenue (formerly gross margin), deducting the cost of magazines sold from the amount of sales recorded. For acquisition and management commissions linked to sales of insurance policies, net sales comprise current and future commissions issued, acquired by the accounting reporting date, net of cancellations.
2 For the digital marketing business, the net revenue (formerly gross margin) represents the total amount of net sales (total invoices issued: fees, commissions and purchases charged back to customers) less the total amount of costs for external purchases made on behalf of customers. It is equal to net sales for the magazines and insurance business lines.

3 EBITDA (earnings before interest, tax, depreciation and amortization) is restated for the IFRS 2 impact of bonus share awards and the IFRS 16 impact relating to the restatement of lease charges.
4 Cash position on the balance sheet net of all financial liabilities.

Attachment

• DEKUPLE_CP_resultats_semestriels_2026_E

H1 2026 RESULTS
DIGITAL MARKETING GROWTH AND IMPROVED PROFITABILITY

• Revenue: €121.9m (+3.9%)
• Net revenue: €90.3m (+2.2%)
• Restated EBITDA: €11.9m (+11.7%)
• Net income (Group share): €6.1m (+58.9%), representing 6.7% of net revenue
• Continued European expansion in Communication and Data Marketing

Paris, September 28, 2026 (7:00 a.m.) – DEKUPLE Group, an international Communication and Data Marketing company, delivered disciplined growth and significantly improved profitability in the first half of 2026.

Bertrand Laurioz, Chairman and Chief Executive Officer of Dekuple Group, said:
“In a persistently demanding environment, DEKUPLE Group continues to deliver disciplined growth while significantly improving profitability. Restated EBITDA increased by 11.7% to €11.9m, bringing the EBITDA margin to 13.2% of net revenue, up 111 basis points compared with a challenging first half of 2025. EBIT increased by 25.3% while net income (Group share) rose by 58.9%.

These results reflect the impact of the investments made in recent years in our expertise, technologies and international development, and reinforce our profitable growth trajectory.

This improvement is notably based on the ramp-up of Digital Marketing, the Group’s main growth driver, and the increasing contribution of our international operations. This momentum also reflects the benefits of the integrated model we are building by bringing together our Consulting, Agencies and Solutions expertise and developing synergies between data, marketing technologies, creativity and artificial intelligence. We are therefore gradually becoming able to further industrialize our offerings, increase their added value and better support our clients across all their marketing needs.

At the same time, we are continuing to manage our historical businesses selectively. In Magazines, we are continuing to digitalize our operations and focusing investments on the highest value-creating levers in a structurally declining press market. With regard to Insurance, the strategic review under way should enable us to identify the most appropriate options to support its long-term development as part of our Ambition 2030 plan.

The marketing industry is rapidly evolving towards more integrated and increasingly performance-oriented models. Advertisers expect their partners to combine strategic expertise, strong command of data, technology and execution capabilities, while providing increasingly precise measurements of investment performance. We have chosen to anticipate this shift by building a multi-expertise model capable of interconnecting these different skills and mobilizing them toward a single objective: creating more value for our clients.

Building on this momentum and a solid financial structure, we approach the second half of the year with confidence. Our priority is clear: continue rolling out Ambition 2030, accelerate our expansion in Europe and strengthen synergies between our businesses in order to become a major growth partner for brands.”

First-half highlights

In the first half of 2026, DEKUPLE Group continued its growth trajectory, supported by the strong performance of its Digital Marketing activities, accelerated international development and continued organic growth.

Digital Marketing activities represented 72.7% of consolidated revenue, compared with 69.6% one year earlier. Their net revenue increased by 8.4%, including 6.0% on a like-for-like basis, driven by strong momentum in Consulting & Technology and Agencies & Solutions.

This momentum was accompanied by strong growth in international activities, whose net revenue increased by 37.1%. International operations now represent 15.3% of Group net revenue, compared with 11.4% one year earlier. The Group also continued to pursue its international external growth strategy, notably through the creation of Das Kapital DEKUPLE Group in the Middle East and the acquisition of Subko & Co in Poland, with their results consolidated from July 1, 2026.

Magazines business recorded a 7.0% decline in net revenue in a structurally declining press market. The Group continues to manage its commercial investments selectively in order to preserve the recurring nature and quality of its revenues.

In Insurance, the strategic review under way is continuing in order to identify the most appropriate options to support the business’s long-term development as part of the Ambition 2030 plan.

First-half results

Consolidated revenue¹ amounted to €121.9m, up 3.9%, while net revenue² reached €90.3m, up 2.2%.

Restated EBITDA³ amounted to €11.9m, up 11.7% compared with a difficult first half of 2025. It represented 13.2% of first-half net revenue, compared with 12.0% in the first half of 2025, an improvement of 111 basis points.

Income from ordinary operations amounted to €8.1m, representing 8.9% of first-half net revenue, compared with €6.5m and 7.4% in the first half of 2025. EBIT also amounted to €8.1m, compared with €6.4m in the first half of 2025. These results notably reflect:

• solid growth in earnings from Agencies & Solutions, driven by the increasing contribution of international operations and the development of technology offerings;
• Consulting profitability remained affected by continued investment in international development, notably in the United States and Spain, and by increased investment in AI and technology, despite a slight improvement in project profitability;
• the lower contribution of the Magazines business to profitability, given the decline in the portfolio.

After a net financial expense of €0.5m and an income tax expense of €1.7m, consolidated net income amounted to €5.8m, representing a net margin of 6.4% of net revenue, compared with 4.2% in the first half of 2025.

After non-controlling interests, net income (Group share) amounted to €6.1m, up 58.9% compared with the first half of 2025.

(€m)	H1 2026	H1 2025	Change
Revenue	121.9	117.4	+3.9%
Net revenue	90.3	88.3	+2.2%
Restated EBITDA	11.9	10.6	+11.7%
As % of net revenue	13.2%	12.0%	+111 bp
Income from ordinary operations	8.1	6.5	+23.5%
As % of net revenue	8.9%	7.4%	+154 bp
EBIT	8.1	6.4	+25.3%
As % of net revenue	8.9%	7.3%	+164 bp
Net financial expense / income	(0.5)	(0.0)
Tax expense	(1.7)	(2.8)
Share of net income from associates	0.0	0.0
Consolidated net income	5.8	3.7	+57.2%
As % of net revenue	6.4%	4.2%	+223 bp
Net income (Group share)	6.1	3.8	+58.9%
As % of net revenue	6.7%	4.3%	+239 bp

Financial position at June 30, 2026

The Group’s shareholders’ equity at June 30, 2026 amounted to €55.6m, up €0.9m compared with December 31, 2025 (€54.7m).

Group cash amounted to €45.3m, compared with €55.0m at December 31, 2025 and €45.8m at June 30, 2025.

Financial debt amounted to €58.0m, down €3.2m compared with year-end 2025 (€61.2m). It includes commitments to buy out minority interests (€20.1m), down from year-end 2025 following additional share acquisitions in certain Group subsidiaries. It also includes €36.4m in bank borrowings, of which €26.2m was drawn under the syndicated credit facility established in November 2025.

Net cash/(debt)⁴ therefore amounted to €(12.7)m, compared with €(6.3)m at year-end 2025 and €(7.8)m at June 30, 2025, reflecting in particular the level of investment and external growth transactions completed over the past twelve months.

Outlook

Building on the momentum recorded in the first half, DEKUPLE Group is continuing to roll out its Ambition 2030 strategic plan, with the aim of accelerating its expansion in Europe while strengthening synergies between its areas of expertise.

The Group is actively developing its digital and international activities, continuing to industrialize marketing performance around the convergence of data, technology, artificial intelligence and creativity, and developing high-value recurring revenues.

Drawing on its financial resources and multi-expertise model, DEKUPLE Group will also continue an active policy of investment in technology and targeted external growth in order to strengthen its European leadership in Communication and Data Marketing.

Additional information

The corporate and consolidated financial statements for the first half of 2026 were approved by the Board of Directors on September 25, 2026. The financial statements have been subject to the usual limited review by the statutory auditors for half-year accounts. The half-year financial report will be published on September 30, 2026, after market close, and will be available on the company website at: https://www.dekuple.com/investisseurs/actualites-documents-presentations/

Next event

Revenue and net revenue for the third quarter of 2026, on November 23, 2026, before market opening.

About Dekuple Group

Dekuple Group is an international player in communication, marketing and data, driven by a unique multi-entrepreneurship model. Its integrated growth platform is built around three interconnected and complementary pillars:

• Advise, with Converteo and its 450 expert consultants
• Create, with its multi-expertise agencies in France and internationally
• Boost, with its Boost Factory bringing together its Data and MarTech solutions

With nearly 70 areas of expertise covering the entire communication and data marketing value chain, the Group supports brands in their differentiation and growth challenges. Its integrated approach, through a full-funnel ecosystem, makes it possible to optimize marketing investments and increase their impact.

Founded in 1972, Dekuple Group is present in Europe, North America, China and the Middle East. Its 1,200 employees support more than 750 major accounts and international mid-sized companies every day. Dekuple is listed on the regulated market of Euronext Paris.

www.dekuple.com

Financial Communications Contacts Actus Finance & Communication Cyril Combe – Analysts – Investors +33 1 53 65 37 94 Fatou-Kiné N’Diaye – Press – Media +33 1 53 67 36 34 dekuple@actus.fr

Dekuple Group Contact Investor Relations & Financial Information + 33 (0)1 41 58 72 03 relations.investisseurs@dekuple.com

---

1 Revenue (determined in line with the French professional status for subscription sales) only include the amount of remuneration paid by magazine publishers; for subscription sales, net sales therefore correspond to a net revenue (formerly gross margin), deducting the cost of magazines sold from the amount of sales recorded. For acquisition and management commissions linked to sales of insurance policies, net sales comprise current and future commissions issued, acquired by the accounting reporting date, net of cancellations.
2 For the digital marketing business, the net revenue (formerly gross margin) represents the total amount of net sales (total invoices issued: fees, commissions and purchases charged back to customers) less the total amount of costs for external purchases made on behalf of customers. It is equal to net sales for the magazines and insurance business lines.

3 EBITDA (earnings before interest, tax, depreciation and amortization) is restated for the IFRS 2 impact of bonus share awards and the IFRS 16 impact relating to the restatement of lease charges.
4 Cash position on the balance sheet net of all financial liabilities.

Attachment

• DEKUPLE_CP_resultats_semestriels_2026_E

LA HULPE, BELGIUM – 28 September 2026, 7:00 a.m. CEST – Banqup Group SA (Euronext: BANQ) (Banqup, Company), a European fintech provider that simplifies financial flows through an innovative secured platform for e-invoicing, e-payment, e-reporting and e-trust solutions with built-in compliance at its core, within a consortium led by Dubai-based Clever Science Computer System Trading Co. LLC, today announced the signing of a major agreement with the UAE Federal Tax Authority (“FTA”) to develop and implement Peppol Corner 5 Access Point.

Within the consortium, Banqup has been selected as a technology provider responsible for supporting the development, implementation and operation of the Peppol Corner 5 Access Point for the FTA. The UAE eInvoicing programme is governed by the Ministry of Finance as the regulatory and policy-making authority, while the FTA serves as the operational body responsible for implementation and administration of taxes in the UAE. The solution will adopt a 5-corner model to provide a structured and secure framework for processing e-invoices through a trusted network of interconnected parties, forming part of the broader UAE eInvoicing ecosystem that includes multiple accredited service providers and participants. It will be implemented in alignment with the Peppol standard and the requirements of the FTA. The UAE’s mandatory e-invoicing system will be rolled out in phases, initially covering both B2B and B2G transactions. The first phase is scheduled to begin on 1 January 2027 and will apply to companies with annual revenue exceeding AED 50 million.

This engagement marks an important step forward in advancing the UAE’s digital transformation agenda. Following this collaboration, the UAE becomes the first country to implement a fully Decentralised Continuous Transaction Control and Exchange (“DCTCE”) model using the Peppol framework. Serving as a key component of this next-generation platform, Banqup’s Corner 5 Peppol solution will enable seamless, secure, and standardised near-real-time exchange of e-invoices and tax data within the FTA’s infrastructure, supporting interoperability across the wider network of accredited eInvoicing service providers operating within the UAE framework.

The new infrastructure will enhance tax administration by reducing the VAT gap, ensuring compliance, and providing the FTA with near-real-time visibility. By automating and standardising invoicing and reporting processes, the solution will drive operational efficiency and fiscal transparency across the UAE.

The agreed project timeline spans seven months, commencing on 27 October 2025. Following the design and implementation phase, which was successfully completed in May 2026 making UAE FTA first ever Corner 5 based entirely on Peppol framework, Banqup will provide managed services and technical support, reinforcing its dedication to sustainable, scalable digital transformation in the public sector. 

Banqup’s selection reflects its proven expertise in delivering government e-invoicing infrastructure for tax administrations, combined with regulatory compliance experience across European markets. With its comprehensive (e-invoicing, e-reporting and e-trust) cloud-based and on-premise platforms, designed for national-scale deployment, Banqup is well positioned to support the delivery of this world-first Peppol-based DCTCE system as part of the UAE’s broader eInvoicing ecosystem.

Koen De Brabander, CEO of Banqup Group, said: “This flagship project with the UAE Federal Tax Authority further cements our position as a global leader in government-grade e-invoicing solutions. We are proud to support the UAE’s digital transformation strategy. Our proven expertise in delivering secure, interoperable, and future-proof invoicing platforms will support the broader network of stakeholders and accredited service providers working together to build a more efficient, compliant, and transparent fiscal ecosystem.

Contact

David Geleyn
Head of Investor Relations – Banqup Group
investor.relations@banqup.com
media@banqup.com 

About Banqup Group

Banqup Group (Euronext Brussels: BANQ) architects the trust infrastructure needed to thrive in a digital-first economy. As a specialized European fintech provider and licensed payment institution, Banqup revolutionizes buying and selling for businesses and governments worldwide by digitalising financial supply chain processes within a secure, tax-compliant business network.

Moving beyond traditional software, Banqup operates a unified, open network platform that links business actors, accounting networks, banks, ERP systems, and tax authorities. Built around four interconnected pillars—e-invoicing, e-payments, e-reporting, and e-trust—Banqup enables digitisation of end-to-end order-to-cash and procure-to-pay workflows in full compliance with different regulatory frameworks.

Headquartered in Belgium with a history of pioneering digital transformation since 2001, Banqup is powering growth through effortless financial flows.

To learn more, visit www.banqup.com.

Cautionary note regarding forward-looking statements: The statements contained herein may include prospects, statements of future expectations, opinions, and other forward-looking statements in relation to the expected future performance of Banqup Group and the markets in which it is active. Such forward-looking statements are based on management’s current views and assumptions regarding future events. By nature, they involve known and unknown risks, uncertainties, and other factors that appear justified at the time at which they are made but may not turn out to be accurate. Actual results, performance or events may, therefore, differ materially from those expressed or implied in such forward-looking statements. Except as required by applicable law, Banqup Group does not undertake any obligation to update, clarify or correct any forward-looking statements contained in this press release in light of new information, future events or otherwise and disclaims any liability in respect hereto. The reader is cautioned not to place undue reliance on forward-looking statements.

Attachment

• Press Release – UAE

LA HULPE, BELGIUM – 28 September 2026, 7:00 a.m. CEST – Banqup Group SA (Euronext: BANQ) (Banqup, Company), a European fintech provider that simplifies financial flows through an innovative secured platform for e-invoicing, e-payment, e-reporting and e-trust solutions with built-in compliance at its core, within a consortium led by Dubai-based Clever Science Computer System Trading Co. LLC, today announced the signing of a major agreement with the UAE Federal Tax Authority (“FTA”) to develop and implement Peppol Corner 5 Access Point.

Within the consortium, Banqup has been selected as a technology provider responsible for supporting the development, implementation and operation of the Peppol Corner 5 Access Point for the FTA. The UAE eInvoicing programme is governed by the Ministry of Finance as the regulatory and policy-making authority, while the FTA serves as the operational body responsible for implementation and administration of taxes in the UAE. The solution will adopt a 5-corner model to provide a structured and secure framework for processing e-invoices through a trusted network of interconnected parties, forming part of the broader UAE eInvoicing ecosystem that includes multiple accredited service providers and participants. It will be implemented in alignment with the Peppol standard and the requirements of the FTA. The UAE’s mandatory e-invoicing system will be rolled out in phases, initially covering both B2B and B2G transactions. The first phase is scheduled to begin on 1 January 2027 and will apply to companies with annual revenue exceeding AED 50 million.

This engagement marks an important step forward in advancing the UAE’s digital transformation agenda. Following this collaboration, the UAE becomes the first country to implement a fully Decentralised Continuous Transaction Control and Exchange (“DCTCE”) model using the Peppol framework. Serving as a key component of this next-generation platform, Banqup’s Corner 5 Peppol solution will enable seamless, secure, and standardised near-real-time exchange of e-invoices and tax data within the FTA’s infrastructure, supporting interoperability across the wider network of accredited eInvoicing service providers operating within the UAE framework.

The new infrastructure will enhance tax administration by reducing the VAT gap, ensuring compliance, and providing the FTA with near-real-time visibility. By automating and standardising invoicing and reporting processes, the solution will drive operational efficiency and fiscal transparency across the UAE.

The agreed project timeline spans seven months, commencing on 27 October 2025. Following the design and implementation phase, which was successfully completed in May 2026 making UAE FTA first ever Corner 5 based entirely on Peppol framework, Banqup will provide managed services and technical support, reinforcing its dedication to sustainable, scalable digital transformation in the public sector. 

Banqup’s selection reflects its proven expertise in delivering government e-invoicing infrastructure for tax administrations, combined with regulatory compliance experience across European markets. With its comprehensive (e-invoicing, e-reporting and e-trust) cloud-based and on-premise platforms, designed for national-scale deployment, Banqup is well positioned to support the delivery of this world-first Peppol-based DCTCE system as part of the UAE’s broader eInvoicing ecosystem.

Koen De Brabander, CEO of Banqup Group, said: “This flagship project with the UAE Federal Tax Authority further cements our position as a global leader in government-grade e-invoicing solutions. We are proud to support the UAE’s digital transformation strategy. Our proven expertise in delivering secure, interoperable, and future-proof invoicing platforms will support the broader network of stakeholders and accredited service providers working together to build a more efficient, compliant, and transparent fiscal ecosystem.

Contact

David Geleyn
Head of Investor Relations – Banqup Group
investor.relations@banqup.com
media@banqup.com 

About Banqup Group

Banqup Group (Euronext Brussels: BANQ) architects the trust infrastructure needed to thrive in a digital-first economy. As a specialized European fintech provider and licensed payment institution, Banqup revolutionizes buying and selling for businesses and governments worldwide by digitalising financial supply chain processes within a secure, tax-compliant business network.

Moving beyond traditional software, Banqup operates a unified, open network platform that links business actors, accounting networks, banks, ERP systems, and tax authorities. Built around four interconnected pillars—e-invoicing, e-payments, e-reporting, and e-trust—Banqup enables digitisation of end-to-end order-to-cash and procure-to-pay workflows in full compliance with different regulatory frameworks.

Headquartered in Belgium with a history of pioneering digital transformation since 2001, Banqup is powering growth through effortless financial flows.

To learn more, visit www.banqup.com.

Cautionary note regarding forward-looking statements: The statements contained herein may include prospects, statements of future expectations, opinions, and other forward-looking statements in relation to the expected future performance of Banqup Group and the markets in which it is active. Such forward-looking statements are based on management’s current views and assumptions regarding future events. By nature, they involve known and unknown risks, uncertainties, and other factors that appear justified at the time at which they are made but may not turn out to be accurate. Actual results, performance or events may, therefore, differ materially from those expressed or implied in such forward-looking statements. Except as required by applicable law, Banqup Group does not undertake any obligation to update, clarify or correct any forward-looking statements contained in this press release in light of new information, future events or otherwise and disclaims any liability in respect hereto. The reader is cautioned not to place undue reliance on forward-looking statements.

Attachment

• Press Release – UAE